intranas
deliveri
dna
vaccin
becom
popular
research
area
recent
offer
distinguish
advantag
parenter
rout
vaccin
administr
nasal
mucosa
site
vaccin
administr
stimul
respiratori
mucos
immun
interact
nasopharyngealassoci
lymphoid
tissu
nalt
differ
kind
dna
vaccin
investig
provid
protect
respiratori
infecti
diseas
includ
tuberculosi
coronaviru
influenza
respiratori
syncyti
viru
rsv
etc
dna
vaccin
sever
attract
develop
potenti
produc
crossprotect
toward
differ
viru
subtyp
enabl
possibl
mass
manufactur
rel
short
time
better
safeti
profil
biggest
obstacl
dna
vaccin
low
immunogen
one
approach
enhanc
efficaci
dna
vaccin
improv
dna
deliveri
effici
review
provid
insight
develop
intranas
dna
vaccin
respiratori
infect
special
attent
paid
strategi
improv
deliveri
dna
vaccin
use
nonvir
deliveri
agent
major
current
licens
vaccin
prevent
infecti
diseas
liveattenu
vaccin
inactiv
vaccin
subunit
vaccin
pro
con
liveattenu
vaccin
stimul
cellular
humor
immun
respons
induc
prolong
immun
close
resembl
natur
infect
howev
safeti
concern
associ
use
live
attenu
viru
bacteri
vaccin
may
revert
diseas
caus
form
also
difficult
target
multipl
viral
subtyp
pathogen
use
liveattenu
vaccin
inactiv
subunit
vaccin
safer
option
replic
caus
diseas
confer
protect
mainli
humor
immun
respons
littl
cellular
immun
induc
immun
last
shorter
period
time
therefor
supplement
dose
alway
requir
recent
year
dna
vaccin
attract
consider
attent
altern
vaccin
method
infecti
diseas
potenti
provid
broad
immun
respons
similar
liveattenu
vaccin
without
risk
associ
replic
microorgan
dna
vaccin
approach
reli
situ
product
target
antigen
plasmid
dna
encod
antigen
protein
deliv
appropri
tissu
bodi
lead
express
desir
antigen
elicit
specif
immunogen
respons
therebi
induc
immun
protect
pathogen
sinc
host
cell
respons
antigen
product
natur
glycosyl
fold
protein
warrant
plasmid
dna
encod
differ
bacteri
viral
antigen
test
immunogen
protect
efficaci
vivo
confirm
clinic
potenti
addit
dna
vaccin
offer
sever
distinct
advantag
convent
vaccin
doubl
helic
structur
dna
simpl
stabl
high
temperatur
allow
easi
storag
transport
largescal
manufactur
dna
vaccin
conveni
rel
cheap
requir
standard
clone
antigen
code
sequenc
plasmid
vector
avoid
complex
procedur
repeat
cultur
inactiv
infecti
pathogen
purif
recombin
protein
apart
advantag
physicochem
properti
dna
vaccin
abil
gener
cellular
immun
addit
humor
immun
also
highli
flexibl
encod
sever
type
gene
includ
viral
bacteri
antigen
well
immunolog
protein
advantag
dna
vaccin
compar
convent
vaccin
summar
tabl
field
dna
vaccin
develop
rapidli
dna
vaccin
current
approv
veterinari
use
variou
infecti
diseas
howev
result
clinic
trial
less
encourag
dna
vaccin
gener
safe
well
toler
human
immun
respons
often
low
offer
suffici
protect
earli
studi
dna
vaccin
alon
abl
gener
cell
respons
magnitud
enough
protect
difficult
diseas
human
recent
attempt
still
fail
overcom
problem
plasmid
pthr
dna
vaccin
candid
evalu
phase
clinic
trial
healthi
volunt
show
weak
immunogen
human
signific
cellmedi
immun
respons
differ
found
vaccin
recipi
placebo
recipi
addit
hiv
specif
antibodi
product
anoth
phase
trial
hiv
vaccin
use
dna
primeviru
vector
vaccin
boost
strategi
healthi
volunt
prove
effect
elicit
tcell
respons
incap
induc
neutral
antibodi
activ
human
gag
dna
vaccin
without
interleukin
il
andor
plasmid
cytokin
adjuv
report
produc
poor
cellular
immunogen
vaccineinduc
antigag
humor
immun
respons
healthi
volunt
contrast
previou
find
macaqu
sever
strategi
introduc
optim
dna
vaccin
one
enhanc
dna
deliveri
effici
focu
review
dna
deliveri
effici
depend
administr
rout
deliveri
system
use
mucos
surfac
attract
site
vaccin
administr
infecti
diseas
portal
entri
mani
pathogen
vaccin
mucos
site
pathogen
initi
infect
efficaci
parenter
administr
invad
pathogen
may
neutral
front
line
gener
system
effect
particular
intranas
vaccin
extens
investig
recent
year
vaccin
nasal
mucosa
stimul
respiratori
mucos
immun
interact
nasopharyngealassoci
lymphoid
tissu
nalt
larg
amount
local
lymphocyt
present
furthermor
intranas
deliveri
needlefre
noninvas
rout
administr
possibl
selfadministr
intranas
dna
vaccin
becom
promis
approach
offer
immun
protect
variou
pathogen
affect
respiratori
system
includ
tuberculosi
coronaviru
infect
influenza
respiratori
syncyti
viru
rsv
articl
current
develop
dna
vaccin
deliveri
system
specif
design
intranas
administr
respiratori
infecti
diseas
discuss
detail
typic
dna
vaccin
administ
intramuscular
inject
although
administr
rout
includ
intraderm
subcutan
oral
intranas
rout
also
investig
upon
administr
somat
cell
eg
myocyt
keratinocyt
profession
antigen
present
cell
apc
transfect
antigen
express
intracellularli
humor
cellmedi
immun
activ
offer
broad
immun
protect
hostsynthes
antigen
becom
subject
immun
surveil
context
major
histocompat
complex
mhc
class
class
ii
molecul
apc
antigen
express
apc
travel
drain
lymph
node
present
antigen
peptidemhc
complex
stimul
cell
altern
b
cell
activ
initi
antibodi
product
cascad
major
advantag
dna
vaccin
abil
activ
tcell
cytotox
lymphocyt
import
control
infect
action
lack
inactiv
subunit
vaccin
induct
tcell
dna
vaccin
occur
two
major
way
direct
dna
transfect
apc
dendrit
cell
dc
ii
crosspresent
occur
somat
cell
myocyt
transfect
dna
express
antigen
taken
apc
transfect
apoptot
cell
phagocytos
apc
mechan
dna
vaccin
illustr
figur
interest
note
immun
may
occur
rapidli
dna
vaccin
express
antigen
antigen
express
somat
cell
may
qualit
major
player
elicit
immun
respons
compar
secondari
role
somat
cell
bone
marrow
deriv
antigen
present
cell
apc
activ
import
indic
success
induct
dna
vaccin
studi
dna
vaccin
deliv
skin
mous
ear
gene
gun
immun
respons
produc
inocul
site
ie
ear
rapidli
remov
immun
antigen
express
indic
mobil
cell
import
elabor
immun
anoth
similar
studi
surgic
remov
inject
muscl
within
min
dna
vaccin
administr
affect
magnitud
longev
antibodi
respons
encod
antigen
result
confirm
import
apc
somat
cell
myocyt
keratinocyt
elicit
immun
respons
earli
studi
show
dna
vaccin
poorli
immunogen
low
level
antigen
express
improv
immunogen
dna
vaccin
cpg
motif
commonli
employ
construct
plasmid
backbon
bacteri
viral
dna
contain
unmethyl
cpg
motif
wherea
mammalian
cell
cpg
dinucleotid
motif
rare
usual
methyl
demonstr
unmethyl
cpg
motif
immunostimulatori
effect
consid
mammalian
cell
pathogenassoci
molecular
pattern
pamp
unmethyl
cpg
activ
innat
immun
cell
bind
tolllik
receptor
constitut
express
endosom
compart
apc
b
cell
bound
dna
rich
cpg
motif
activ
immun
system
initi
proinflammatori
respons
result
product
cytokin
interferon
ifn
interleukin
il
howev
found
defici
mice
also
respond
dna
vaccin
suggest
may
sole
mediat
adjuv
effect
dna
vaccin
also
interact
cytoplasm
dna
sensor
includ
tankbind
kinas
stimul
ifn
gene
sting
activ
tlrindepend
pathway
induc
pathway
crucial
contribut
immunogen
dna
vaccin
although
persist
antigen
express
dna
vaccin
usual
expect
provid
longterm
immun
protect
infecti
diseas
effect
sustain
express
antigen
must
care
examin
control
report
prolong
express
antigen
may
lead
switch
ifn
antivir
cytokin
immunosuppress
cytokin
may
deplet
pool
memori
cell
evalu
efficaci
dna
vaccin
human
serum
antibodi
titer
enzymelink
immunospot
elispot
assay
commonli
employ
method
measur
immunogen
respons
although
induct
antigenspecif
immun
effector
immun
process
impli
antibodi
cytokin
repres
surrog
correl
vaccin
efficaci
earli
stage
vaccin
develop
vitro
serum
antibodi
elispot
assay
direct
detect
indic
clinic
potenti
vaccin
formul
later
stage
develop
morbid
mortal
especi
improv
surviv
rate
vaccin
anim
upon
target
pathogen
challeng
certain
way
confirm
protect
efficaci
vaccin
ultim
goal
vaccin
prevent
target
diseas
efficaci
vaccin
influenza
vaccin
could
monitor
human
subsequ
influenza
epidem
season
challeng
control
influenza
viru
howev
lethal
viru
challeng
studi
difficult
conduct
directli
human
henc
measur
antibodi
product
immun
respons
human
remain
direct
way
assess
vaccin
efficaci
longer
studi
requir
investig
vaccin
inde
abl
prevent
diseas
safeti
alway
primari
concern
vaccin
product
dna
vaccin
gener
consid
safer
convent
vaccin
approach
lack
risk
revers
diseas
caus
state
secondari
infect
similar
gene
therapi
major
safeti
issu
relat
dna
vaccin
risk
integr
plasmid
dna
host
genom
caus
insert
mutagenesi
may
lead
inactiv
tumour
suppressor
gene
activ
oncogen
result
devast
advers
effect
accord
preclin
clinic
studi
littl
evid
genom
integr
follow
dna
vaccin
administr
risk
integr
found
significantli
lower
spontan
mutat
rate
anoth
safeti
issu
dna
vaccin
relat
develop
antidna
immun
respons
anim
studi
show
increas
antinuclear
antidna
antibodi
dna
vaccin
clinic
trial
studi
sign
symptom
autoimmun
marker
autoimmun
sometim
monitor
human
subject
evid
autoimmun
associ
dna
vaccin
suggest
proper
purif
e
coli
effect
prevent
pathogen
antidna
antibodi
product
antibiot
resist
anoth
issu
relat
dna
vaccin
typic
largescal
manufactur
plasmid
dna
involv
use
antibioticresist
marker
safeti
concern
resist
antibiot
might
introduc
respons
issu
antibioticresist
gene
dna
vaccin
restrict
use
treat
human
infect
altern
use
antibioticresist
gene
avoid
complet
anoth
concern
dna
vaccin
develop
toler
encod
antigen
appear
agerel
newborn
immatur
immun
system
like
develop
toler
rather
protect
expos
foreign
antigen
contrast
immun
instead
toler
occur
dna
vaccin
administ
young
anim
recent
year
increas
concern
vaccin
gener
may
induc
harm
system
inflamm
may
lead
increas
cardiovascular
risk
dna
vaccin
still
consid
rel
new
approach
vaccin
potenti
induc
system
inflamm
must
overlook
report
littl
local
inflammatori
infiltr
observ
dna
vaccin
inject
site
especi
acut
effect
vaccin
disappear
first
clinic
trial
dnabas
vaccin
infect
publish
asymptomat
hivinfect
patient
use
antivir
drug
immun
well
toler
neither
local
system
reaction
laboratori
abnorm
detect
three
dose
vaccin
addit
patient
develop
antidna
antibodi
muscl
enzym
elev
consist
chang
lymphocyt
count
occur
anoth
earli
experi
conduct
pig
show
electropor
dna
vaccin
effici
enhanc
immun
respons
also
stimul
inflammatori
respons
accompani
cellular
infiltr
wherea
convent
intramuscular
inject
dna
vaccin
show
low
gene
express
low
inflammatori
cell
infiltr
suggest
improv
antigen
present
one
possibl
mechan
increas
inflammatori
cell
infiltr
may
enhanc
immun
respons
dna
vaccin
deliv
electropor
howev
longterm
safeti
effect
investig
overal
mani
recent
preclin
studi
clinic
trial
indic
dna
vaccin
gener
well
toler
good
safeti
profil
system
inflamm
report
nonetheless
dna
vaccin
rel
new
vaccin
approach
yet
approv
human
use
long
term
safeti
use
must
thoroughli
evalu
routin
prophylact
therapeut
use
human
especi
new
deliveri
system
adjuv
introduc
formul
convent
vaccin
usual
administ
parenter
inject
mainli
target
system
immun
system
elicit
weak
mucos
immun
respons
vaccin
deliv
directli
mucos
site
mucos
immun
respons
effici
potenti
particular
nasal
mucosa
attract
consider
attent
site
vaccin
recent
year
includ
dna
vaccin
due
sever
distinct
advantag
howev
also
formid
barrier
need
overcom
allow
success
develop
intranas
dna
vaccin
intranas
rout
drug
administr
frequent
use
treat
local
condit
nasal
congest
allergi
intranas
administr
character
easi
administr
rapid
onset
action
avoid
firstpass
metabol
needlefre
administr
rout
noninvas
avoid
risk
spread
bloodborn
infect
particular
problem
develop
countri
desir
featur
lead
explor
system
deliveri
polar
drug
biomolecul
includ
vaccin
feasibl
administr
rout
intranas
vaccin
investig
decad
major
current
avail
vaccin
administ
intramuscular
subcutan
intraderm
inject
although
parenter
rout
administr
effect
induc
system
immun
respons
ineffect
induc
local
immun
mucos
site
mani
pathogen
infect
human
mucos
surfac
mucos
vaccin
could
provid
better
protect
inject
vaccin
infecti
diseas
induc
system
mucos
immun
sinc
strongest
immun
respons
usual
induc
vaccin
site
adjac
mucos
site
intranas
immun
abl
elicit
protect
immun
respons
effect
lung
upper
respiratori
tract
nasal
mucosa
appear
appropri
site
vaccin
administr
respiratori
infecti
diseas
nasal
caviti
first
site
contact
inhal
macromolecul
common
site
infect
respiratori
pathogen
also
stimul
respiratori
mucos
immun
interact
nalt
current
licens
intranas
vaccin
includ
flumist
liveattenu
vaccin
target
influenza
type
b
nasovac
liveattenu
vaccin
target
influenza
viru
apart
liveattenu
vaccin
intranas
rout
administr
also
favor
proteinbas
vaccin
evidenc
mani
studi
includ
intranas
pneumococc
protein
immun
pneumonia
recent
studi
intranas
respiratori
syncyti
viru
rsv
vaccin
base
recombin
fusion
protein
success
intranas
liveattenu
viru
vaccin
promis
effect
proteinbas
vaccin
highli
plausibl
dna
vaccin
adopt
deliveri
rout
achiev
effici
immun
well
establish
mucos
vaccin
induc
humor
cellmedi
immun
respons
system
well
mucos
site
immun
respons
induc
mucos
vaccin
mainli
initi
specif
mucosaassoci
lymphoid
tissu
malt
malt
line
nasal
caviti
known
nasopharyngealassoci
lymphoid
tissu
nalt
includ
waldey
ring
tonsil
adenoid
collect
isol
subepitheli
lymphoid
follicl
nalt
rich
immunocompet
cell
includ
b
cell
cell
phagocyt
apc
macrophag
dc
addit
overli
epithelium
mucos
follicl
form
special
cell
layer
cell
microfold
apic
surfac
known
microfold
cell
cell
cell
play
crucial
role
initi
phase
induct
mucos
immun
respons
therefor
cell
target
import
strategi
achiev
mucos
immun
cell
effici
take
particl
epitheli
surfac
transport
across
cell
releas
underli
extracellular
space
process
known
transcytosi
basal
surfac
cell
membran
cell
extens
fold
around
underli
immun
cell
includ
b
cell
cell
apc
take
particl
releas
cell
process
antigen
present
initi
mucos
immun
respons
summar
figur
upon
b
cell
activ
follow
nasal
vaccin
product
antigenspecif
secretori
immunoglobulin
siga
trigger
siga
critic
compon
mucos
immun
system
proteas
resist
effect
bind
neutral
pathogen
toxic
product
nasal
mucosa
surfac
despit
proteas
rich
environ
therebi
prevent
pathogen
breach
mucos
barrier
local
immunoglobulin
g
igg
product
also
detect
mucos
vaccin
partli
contribut
neutral
pathogen
howev
igg
concentr
around
lower
siga
due
suscept
proteas
degrad
inde
siga
provid
first
barrier
pathogen
invas
induct
potent
siga
respons
import
goal
mucos
vaccin
addit
nasal
immun
also
result
product
serum
iga
serum
igg
potenti
neutral
pathogen
enter
mucosa
prevent
system
spread
dc
mucosa
present
antigen
activ
cell
may
migrat
proxim
drain
lymph
node
dissemin
immun
respons
site
bodi
apart
humor
immun
respons
cellmedi
immun
respons
also
induc
mucos
vaccin
although
cytotox
cell
mucos
tissu
may
prevent
pathogen
entri
crucial
clearanc
pathogen
overal
cell
nalt
involv
regul
humor
cellmedi
immun
respons
local
also
system
offer
broad
immun
respons
sinc
nasal
mucosa
import
portal
entri
respiratori
pathogen
nasal
rout
becom
attract
administr
vaccin
reinforc
nasal
mucos
immun
respons
defens
mechan
nasal
caviti
present
signific
barrier
entri
pathogen
potenti
harm
substanc
howev
also
becom
import
barrier
intranas
dna
vaccin
nasal
mucosa
constitut
outmost
layer
nasal
passag
consist
mainli
ciliat
columnar
cell
noncili
columnar
cell
goblet
cell
basal
cell
proport
cell
vari
differ
region
nasal
caviti
nasal
mucu
produc
goblet
cell
submucos
gland
provid
protect
physic
barrier
foreign
materi
highli
viscou
gellik
heterogen
mixtur
contain
glycoprotein
enzym
immunoglobulin
salt
protein
lipid
compon
dna
vaccin
administ
nasal
caviti
propens
trap
nasal
mucu
lead
enzymat
degrad
effect
mucu
depend
viscos
pore
size
affect
diffus
agent
deliv
mucos
surfac
addit
entrap
dna
vaccin
may
also
remov
mucociliari
action
ciliat
cell
drive
overli
mucu
layer
continu
toward
nasopharynx
clear
mucu
nasal
passag
result
short
resid
time
mucos
surfac
anoth
challeng
intranas
vaccin
vaccin
formul
may
dilut
mucos
fluid
bulk
fluid
may
limit
effect
deposit
onto
epithelium
mucos
system
overcom
barrier
safe
effici
dna
deliveri
system
must
develop
ideal
deliveri
system
target
mucos
apc
antigen
process
lead
specif
b
cell
activ
ultim
goal
dna
deliveri
system
facilit
uptak
dna
target
tissu
cell
protect
dna
enzymat
degrad
increas
resid
time
formul
nasal
caviti
enhanc
express
antigen
increas
immun
respons
without
compromis
safeti
differ
dna
vaccin
deliveri
system
current
investig
intranas
administr
discuss
detail
section
despit
numer
merit
intranas
immun
potenti
hazard
nasal
vaccin
must
overlook
concern
safeti
intranas
vaccin
rais
intranas
inactiv
influenza
vaccin
call
nasalflu
develop
berna
biotech
found
associ
bell
palsi
temporari
neurolog
paralysi
one
side
face
nasalflu
consist
influenza
virosom
formul
contain
hemagglutinin
ha
neuraminidas
na
antigen
well
heatlabil
enterotoxin
lt
e
coli
mucos
adjuv
sinc
parenter
administr
inactiv
influenza
vaccin
confer
increas
risk
bell
palsi
natur
influenza
viru
infect
soon
conclud
adjuv
lt
e
coli
culprit
case
reason
flumist
nasovac
intranas
liveattenu
influenza
vaccin
without
enterotoxin
adjuvantsdo
appear
confer
increas
risk
condit
understand
pathogenesi
bell
palsi
connect
nasalflu
becom
import
research
focu
vaccin
develop
follow
intranas
administr
mice
enterotoxin
found
olfactori
nerv
olfactori
bulb
extend
period
sinc
olfactori
epithelium
part
central
nervou
system
cn
expos
extern
environ
drug
nanoparticl
includ
intranas
vaccin
may
bypass
blood
brain
barrier
enter
cn
olfactori
transmiss
reason
concern
neurotox
effect
vaccin
contain
enterotoxin
adjuv
intranas
administr
nasal
deliveri
neuronalbind
ltderiv
adjuv
inadvis
toxinderiv
adjuv
cholera
toxinderiv
ctadd
doubl
mutant
cholera
enterotoxin
ct
claim
safe
effect
adjuv
candid
without
caus
inflamm
cn
toxic
nevertheless
thorough
evalu
must
perform
use
toxin
deriv
intranas
vaccin
adjuv
tremend
effort
focus
develop
altern
adjuv
better
safeti
profil
mankind
haunt
respiratori
infecti
diseas
aeon
creat
public
health
concern
sinc
ancient
time
emerg
new
drugresist
strain
becom
challeng
protect
public
infect
use
convent
vaccin
method
dna
vaccin
huge
potenti
prevent
respiratori
infect
due
abil
offer
broad
immun
rel
rapid
process
design
new
dna
vaccin
construct
possibl
largescal
product
short
period
time
section
four
pathogen
caus
sever
diseas
airway
highlight
includ
tuberculosi
coronaviru
influenza
respiratori
syncyti
viru
brief
discuss
current
dna
vaccin
develop
infect
tuberculosi
tb
bacteri
infecti
diseas
caus
mycobacterium
tuberculosi
transmit
respiratori
aerosol
tb
becom
major
public
health
problem
threaten
progress
made
tb
care
control
world
tb
vaccin
current
avail
attenu
strain
mycobacterium
bovi
bacillu
bcg
develop
howev
efficaci
adult
pulmonari
tb
remain
controversi
emerg
drugresist
tb
increas
rate
hivaid
tb
coinfect
new
effect
tb
vaccin
urgent
need
effect
protect
immun
mycobacterium
tuberculosi
requir
cellmedi
immun
respons
includ
cell
sinc
dna
vaccin
abil
induc
strong
cellular
immun
becom
attract
vaccin
approach
tb
first
two
studi
report
promis
protect
effect
dna
vaccin
tuberculosi
conduct
mice
use
plasmid
dna
encod
antigen
mycobacterium
tuberculosi
kda
heatshock
protein
mycobacterium
lepra
differ
antigen
fusion
protein
also
explor
dna
vaccin
tuberculosi
dna
vaccin
encod
mycobacteri
protein
either
secret
mycobacteri
cultur
filtrat
expos
mycobacteri
cellwal
surfac
coronavirus
cov
potenti
lethal
pathogen
character
presenc
spike
protein
viral
surfac
two
new
strain
sever
acut
respiratori
syndrom
cov
sarscov
middl
east
respiratori
syndrom
cov
merscov
identifi
could
caus
acut
respiratori
distress
syndrom
ard
associ
high
mortal
rate
cov
vaccin
histor
exhibit
poor
capac
crossprotect
develop
safe
broad
spectrum
effect
vaccin
rapidli
made
avail
emerg
epidem
requir
current
approv
vaccin
human
cov
infect
studi
focus
sarscov
spike
nucleocapsid
protein
immunodomin
cov
protein
antigen
interest
vaccin
develop
dna
vaccin
encod
nucleocapsid
protein
induc
strong
cellmedi
immun
protect
high
titer
viral
challeng
addit
nucleocapsid
dna
vaccin
could
induc
delayedtyp
hypersensit
even
absenc
antibodi
respons
effect
observ
spike
protein
dna
vaccin
influenza
caus
orthomyxovirus
rna
virus
affect
mainli
upper
respiratori
tract
recent
year
zoonot
variant
influenza
becom
seriou
threat
human
health
includ
avian
influenza
viru
swine
influenza
viru
although
anim
virus
distinct
human
influenza
virus
usual
transmit
human
may
still
occasion
infect
human
caus
sever
pneumonia
even
death
furthermor
viru
acquir
capac
spread
easili
among
peopl
could
start
epidem
even
pandem
protect
popul
influenza
infect
highli
effect
broadspectrum
influenza
vaccin
could
prepar
rapidli
demand
current
influenza
vaccin
mainli
target
induct
antibodi
viral
glycoprotein
particularli
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
antibodi
ha
neutral
infect
viru
antibodi
na
prevent
releas
viru
infect
cell
apart
surfac
glycoprotein
intern
protein
nucleoprotein
np
matrix
protein
well
ion
channel
protein
highli
conserv
within
differ
subtyp
also
becom
attract
target
antigen
vaccin
provid
broad
crossstrain
protect
dna
vaccin
potenti
solv
mismatch
problem
shorten
lag
time
particularli
use
face
influenza
pandem
addit
strategi
combin
immun
dna
vaccin
encod
surfac
protein
eg
ha
intern
protein
np
could
offer
better
protect
influenza
viru
singl
dna
vaccin
alon
mice
ferret
success
dna
vaccin
variou
anim
model
sever
phase
ii
clinic
trial
dna
vaccin
influenza
carri
result
far
encourag
demonstr
safeti
immunogen
respons
human
respiratori
syncyti
viru
rsv
singl
strand
rna
pneumoviru
belong
paramyxovirida
famili
account
one
lead
pathogenes
lower
respiratori
tract
infect
hospit
infant
young
children
well
elderli
highrisk
popul
immun
rsv
depend
induct
antibodi
respons
addit
cell
respons
shown
reduc
diseas
sever
although
matern
antibodi
appear
protect
infant
infect
amount
gradual
decreas
within
first
month
life
human
rsv
lack
approv
vaccin
antivir
therapi
prevent
infant
childhood
infect
vaccin
abl
induc
immun
respons
rapidli
birth
could
challeng
task
immun
system
first
month
life
immatur
persist
matern
antibodi
may
limit
induct
infant
antibodi
respons
three
rsv
protein
name
fusion
f
protein
attach
glycoprotein
g
matrix
protein
lead
candid
rsv
vaccin
develop
deliveri
one
major
barrier
dna
vaccin
administr
nake
dna
usual
ineffici
small
fraction
dna
taken
cell
subsequ
express
dna
neg
charg
hydrophil
macromolecul
incap
cross
biolog
membran
unassist
therefor
safe
effici
dna
deliveri
system
sometim
employ
adjuv
facilit
effici
cellular
uptak
dna
vaccin
promot
dna
releas
insid
cell
induc
high
level
antigen
express
henc
immun
respons
physic
method
gene
gun
also
known
particlemedi
epiderm
deliveri
studi
deliv
dna
skin
gold
bead
coat
dna
vaccin
discharg
directli
cytoplasm
nuclei
skin
cell
method
deliveri
enjoy
success
applic
intranas
administr
consider
effort
made
improv
efficaci
develop
effect
dna
deliveri
system
intranas
vaccin
formul
dna
vaccin
synthet
nonvir
vector
polymer
nanomicroparticl
liposom
report
increas
uptak
plasmid
dna
cell
increas
immunogen
anim
model
human
addit
adjuv
may
also
use
improv
immunogen
deliveri
system
elicit
immun
respons
dna
vaccin
mainli
reli
profession
apc
present
antigen
b
cell
cell
ensur
good
immun
respons
dna
vaccin
deliveri
system
abl
target
apc
addit
cell
nalt
major
site
pathogen
entri
also
target
dna
vaccin
apc
heterogen
group
immunocompet
cell
mediat
immun
respons
process
present
antigen
cell
cell
recogn
antigen
peptid
fragment
surfac
apc
cell
receptor
helper
cell
recogn
antigen
associ
class
ii
mhc
protein
wherea
cytotox
cell
recogn
antigen
associ
class
mhc
protein
addit
costimulatori
signal
produc
apc
lead
activ
cell
nonprofession
apc
lack
costimulatori
signal
therefor
simul
cell
suffici
three
type
profession
apc
name
dc
macrophag
b
cell
among
dc
broadest
rang
antigen
present
consid
effici
cell
induct
regul
immun
respons
play
central
role
bridg
innat
immun
system
adapt
immun
system
achiev
effici
dna
vaccin
logic
target
plasmid
dna
dc
encod
antigen
could
express
endogen
dc
express
larg
number
surfac
receptor
ctype
lectin
receptor
clr
tlr
engag
recognit
pathogen
report
target
antigen
receptor
dc
significantli
enhanc
immun
respons
receptor
could
exploit
dna
vaccin
target
aid
antibodi
natur
ligand
particular
clr
endocyt
receptor
recogn
carbohydr
structur
resembl
pathogen
cellwal
compon
respons
intern
pathogen
one
commonli
studi
receptor
vaccin
target
dc
ctype
lectin
receptor
specif
express
dc
howev
ligand
yet
identifi
sever
studi
demonstr
employ
antibodi
achiev
dc
target
dna
vaccin
includ
intranas
immun
anoth
identifi
dcspecif
target
ctype
lectin
domain
famili
member
activ
lead
stimul
antibodi
product
altern
dc
could
target
use
natur
ligand
mannos
receptor
howev
effect
target
compon
mucos
vaccin
remain
investig
also
sever
molecul
investig
target
apc
gener
one
wide
studi
molecul
ligand
ligand
growth
factor
stimul
prolifer
hematopoiet
cell
bind
fmslike
tyrosin
kinas
receptor
express
hematopoiet
tissu
restrict
progenitor
includ
dc
progenitor
vivo
treatment
ligand
found
upregul
number
dc
activ
furthermor
ligand
treatment
could
also
enhanc
immun
respons
deliv
via
mucos
rout
report
plasmid
dna
encod
ligand
coadminist
plasmid
encod
protein
antigen
effect
immun
respons
induc
addit
apc
target
abil
ligand
effici
safe
mucos
adjuv
facilit
expans
dc
follow
nasal
administr
discuss
section
improv
cell
uptak
anoth
strategi
enhanc
vaccin
immun
effect
mucos
immun
often
correl
uptak
antigen
mucos
induct
tissu
nalt
upper
respiratori
tract
follow
intranas
immun
sinc
cell
respons
antigen
sampl
mucos
surfac
eventu
antigen
present
mucos
b
cell
target
vaccin
cell
effect
method
achiev
strong
immun
respons
particl
size
import
paramet
cell
uptak
number
studi
conduct
identifi
optim
particl
size
cellular
uptak
mucos
system
studi
suggest
particl
size
less
optim
oral
vaccin
deliveri
peyer
patch
cell
uptak
anoth
nalt
nanoparticl
uptak
studi
also
suggest
particl
submicron
size
optim
mucos
cell
uptak
gener
accept
nalt
cell
uptak
nanos
particl
rapidli
definit
size
rang
establish
apart
cellular
uptak
particl
size
also
affect
kinet
lymphat
drainag
appear
nanoparticl
less
nm
readili
transport
drain
lymph
compar
larger
particl
apart
control
particl
size
achiev
specif
target
passiv
inclus
target
ligand
could
also
increas
uptak
cell
number
pathogen
includ
reoviru
salmonella
typhimurium
mycobacterium
tuberculosi
target
cell
mode
entri
host
identifi
key
molecul
express
pathogen
crucial
invas
would
extrem
help
design
effect
deliveri
system
cell
target
one
exampl
relat
reovirus
target
cell
use
surfac
protein
regard
wu
et
al
report
cell
target
dna
vaccin
deliveri
system
consist
plasmid
dna
recombin
protein
target
ligand
coval
attach
polyllysin
pll
intranas
vaccin
mice
result
show
signific
mucos
siga
product
well
enhanc
cellmedi
immun
ligand
peptid
claudin
target
peptid
cell
specif
monoclon
antibodi
nkm
investig
cell
target
mucos
protein
vaccin
potenti
explor
mucos
dna
vaccin
deliveri
howev
mucos
induc
toler
may
develop
cell
target
deliveri
system
follow
nasal
administr
protein
genet
conjug
ovalbumin
system
unrespons
induc
instead
mucos
iga
immun
therefor
special
attent
must
paid
develop
cell
target
deliveri
system
high
versatil
one
attract
featur
polymerbas
dna
deliveri
system
cation
polym
form
complex
polyplex
nucleic
acid
electrostat
interact
polym
synthesi
rel
cheap
easi
scaleup
particl
size
surfac
properti
polymer
particl
control
use
differ
polym
fabric
method
order
optim
cellular
uptak
transfect
effici
polymer
particl
also
modifi
includ
specif
function
group
ligand
enhanc
immun
respons
polyethylenimin
pei
figur
one
earli
gener
polym
investig
gene
deliveri
high
transfect
effici
frequent
regard
goldstandard
nonvir
gene
deliveri
vector
pei
high
ph
buffer
capac
allow
cargo
escap
endosom
entrap
via
mechan
known
proton
spong
hypothesi
transfect
effici
pei
depend
molecular
weight
level
branch
shim
et
al
describ
use
simpl
method
prepar
pei
kda
dna
complex
vaccin
deliveri
plasmid
dna
encod
sarscov
spike
protein
without
transmembran
domain
employ
studi
mice
immun
intranas
peidna
vaccin
produc
significantli
higher
system
spike
protein
specif
igg
mucos
secretori
iga
lung
compar
immun
nake
dna
furthermor
cellular
immun
respons
detect
improv
specif
cell
respons
anoth
studi
torrieridramard
et
al
demonstr
util
pei
vivojetpei
dna
vaccin
carrier
intranas
administr
plasmid
dna
encod
ha
influenza
virus
use
intranas
administr
peidna
vaccin
induc
cellular
humor
immun
respons
capabl
provid
protect
immun
diverg
viru
subtyp
mice
protect
could
improv
includ
plasmid
dna
encod
na
although
pei
appear
promis
vector
gene
deliveri
includ
dna
vaccin
cation
pei
highli
charg
nonbiodegrad
often
encount
toxic
problem
ignor
regard
mani
group
develop
low
toxic
biodegrad
pei
deriv
gene
deliveri
applic
mann
et
al
develop
pei
deriv
deacyl
pei
dpei
dna
vaccin
deliveri
agent
dpei
nearli
fulli
hydrolys
linear
pei
addit
free
protonat
nitrogen
atom
enabl
effici
bind
dna
reduc
toxic
high
transfect
effici
effect
dna
vaccin
carrier
pulmonari
deliveri
elicit
system
mucos
immun
respons
offer
protect
influenza
challeng
vaccin
mice
system
potenti
exploit
intranas
administr
pei
b
chitosan
c
poli
lacticcoglycol
acid
plga
chitosan
figur
natur
polysaccharid
frequent
studi
drug
deliveri
deriv
chitin
found
abund
crustacean
biodegrad
biocompat
low
toxic
properti
chitosan
tune
chang
molecular
weight
degre
deacetyl
cation
natur
chitosan
strong
bind
affin
nucleic
acid
make
suitabl
candid
dna
deliveri
agent
addit
chitosan
deriv
found
display
strong
mucoadhes
properti
make
particularli
suitabl
facilit
intranas
deliveri
moreov
chitosan
also
report
immunostimul
effect
increas
accumul
activ
macrophag
promot
resist
infect
cytokin
enhanc
cytotox
cell
respons
number
studi
describ
use
chitosan
nanoparticl
deliv
dna
vaccin
formul
intranas
administr
kumar
et
al
report
exploit
chitosan
nanoparticl
deliv
dna
vaccin
acut
respiratori
syncyti
viru
rsv
infect
cocktail
plasmid
dna
encod
number
rsv
antigen
use
complex
chitosan
form
nanoparticl
follow
nasal
vaccin
mice
high
level
serum
igg
mucos
iga
antibodi
well
cytotox
cell
respons
induc
also
elev
lungspecif
product
antivir
action
singl
dose
dna
vaccin
abl
decreas
rsv
titer
primari
infect
similar
studi
perform
anoth
group
describ
use
chitosan
nanoparticl
deliv
plasmid
dna
encod
cell
epitop
protein
rsv
found
intranas
administr
formul
mice
induc
specif
cytotox
cell
respons
compar
induc
via
intraderm
immun
follow
rsv
challeng
nasal
immun
mice
viru
load
lung
significantli
reduc
recent
studi
raghwanshi
et
al
investig
sophist
dc
target
chitosan
nanoparticl
system
nasal
dna
immun
sarscov
chitosan
nanoparticl
surfac
function
ligand
achiev
dc
select
target
deliveri
receptor
ctype
lectin
receptor
found
dc
recognit
uptak
pathogen
author
develop
bifunct
fusion
protein
bffp
vector
consist
truncat
corestreptavidin
fuse
singl
chain
antibodi
corestreptavidin
arm
fusion
protein
bind
biotinyl
chitosan
nanoparticl
scfv
impart
target
specif
dc
receptor
plasmid
dna
encod
nucleocapsid
protein
sarscov
load
chitosan
nanoparticl
follow
intranas
administr
dc
target
nanoparticl
mice
level
mucos
iga
system
igg
nucleocapsid
protein
significantli
enhanc
wherea
mucos
system
immun
respons
detect
nake
plasmid
dna
intranas
administ
result
show
dc
target
deliveri
system
could
promis
strategi
lowdos
nasal
dna
vaccin
enhanc
transfect
effici
chitosan
intranas
administr
thiolat
chitosan
deriv
introduc
thiolat
chitosan
deriv
strong
mucoadhes
properti
due
format
disulphid
bond
thiol
group
modifi
polym
cysteinerich
subdomain
glycoprotein
mucu
layer
lead
improv
mucoadhes
compar
unmodifi
chitosan
improv
sustain
gene
express
could
achiev
vitro
vivo
thiolat
chitosan
deriv
technolog
huge
potenti
adopt
intranas
dna
vaccin
deliveri
poli
lacticcoglycol
acid
plga
figur
synthet
biodegrad
copolym
extens
investig
deliveri
differ
therapeut
agent
includ
protein
nucleic
acid
due
biocompat
excel
safeti
profil
plga
approv
fda
variou
drug
deliveri
system
human
use
sinc
degrad
rate
plga
adjust
modifi
molecular
weight
polym
lactic
acid
glycol
acid
ratio
rate
drug
releas
also
control
accordingli
howev
neg
charg
hydrophob
natur
plga
limit
interact
neg
charg
dna
cation
surfac
modif
plga
micronanoparticl
use
polyc
pei
chitosan
overcom
problem
allow
effici
nucleic
acid
deliveri
strategi
also
appli
deliveri
dna
vaccin
oster
et
al
first
employ
use
microparticl
consist
plga
pei
dna
vaccin
carrier
inject
later
wang
et
al
report
use
chitosan
coat
plga
nanoparticl
deliv
plasmid
dna
encod
fmdv
footandmouth
diseas
viru
capsid
protein
togeth
mucos
adjuv
intranas
vaccin
chitosan
coat
plga
nanoparticl
first
prepar
emulsiondiffusionevapor
techniqu
follow
incorpor
plasmid
dna
nanoparticl
simpl
complex
sampl
freezedri
mannitol
use
intranas
administr
guinea
pig
rat
cellular
humor
immun
respons
detect
also
found
effect
mucos
adjuv
significantli
enhanc
mucos
system
immun
respons
importantli
vaccin
could
offer
immun
protect
anim
fmdv
challeng
liposom
vesicl
compris
phospholipid
bilay
extens
investig
deliv
dna
mammalian
cell
well
vaccin
adjuv
duo
function
make
excel
carrier
system
dna
vaccin
dna
deliveri
neg
charg
plasmid
dna
absorb
surfac
cation
liposom
electrostat
interact
form
complex
altern
dna
encapsul
aqueou
core
cation
nonion
anion
liposom
gener
transfect
effici
cation
liposom
superior
nonion
anion
counterpart
wherea
anion
liposom
provid
enhanc
antibodi
respons
surfac
liposom
decor
target
ligand
antigen
compon
improv
immun
respons
vaccin
formul
current
least
two
approv
liposom
vaccin
formul
market
antigen
deliveri
includ
inflex
v
influenza
vaccin
epax
hepat
vaccin
formul
employ
virosom
technolog
figur
viral
protein
bound
surfac
liposom
array
similar
seen
viral
particl
idea
creat
safe
virallik
particl
induc
strong
protect
immun
respons
similar
technolog
could
appli
dna
vaccin
improv
immunogen
fact
liposom
could
elicit
immun
respons
even
absenc
antigen
demonstr
lay
et
al
dotim
imidazolinium
chlorid
cholesterol
cation
liposomedna
complex
empti
plasmid
dna
vector
incorpor
abl
induc
high
level
antibodi
cell
immun
mice
nonhuman
primat
sinc
lipid
composit
particl
size
surfac
charg
dna
entrap
effici
liposom
affect
immunogen
potenc
paramet
must
care
character
control
major
limit
liposom
dna
vaccin
carrier
longterm
stabil
lyophil
liposom
may
alway
possibl
plasmid
dna
encod
complex
lipid
follow
intranas
immun
mice
nake
dna
complet
ineffect
probabl
due
degrad
dna
mucos
nucleas
lipiddna
formul
capabl
induc
weak
cellmedi
immun
respons
humor
immun
respons
detect
colipid
intranas
formul
compar
anoth
cation
lipid
formul
vaxfectin
use
intramuscular
administr
found
intramuscular
formul
abl
induc
better
immun
respons
howev
combin
intranas
intramuscular
administr
result
stronger
immun
respons
lung
consider
improv
need
develop
formul
intranas
use
rosada
et
al
develop
anoth
liposomebas
formul
dna
vaccin
tb
nontox
cation
liposom
epcdopedotap
egg
use
plasmid
dna
encod
kda
mycobacteri
either
entrap
insid
complex
cation
liposom
intramuscular
intranas
rout
administr
compar
mice
administ
intramuscularli
liposom
formul
ineffect
prevent
tuberculosi
infect
mice
even
two
dose
contrari
complex
liposom
formul
dna
vaccin
abl
offer
protect
infect
even
singl
dose
signific
reduct
coloni
form
unit
cfu
lung
immun
mice
challeng
mycobacterium
tuberculosi
howev
four
dose
intranas
administr
nake
dna
vaccin
fail
offer
protect
author
reason
intranas
vaccin
enhanc
immun
respons
stimul
mucos
immun
nake
dna
fail
cross
mucos
barrier
nasal
caviti
demonstr
import
use
deliveri
carrier
intranas
dna
vaccin
apart
tb
vaccin
studi
report
use
liposom
deliv
influenza
dna
vaccin
cation
liposom
dodacdopepeg
phosphoethanolminedioleylphosphatidylethanolaminepolyethylen
glycol
use
encapsul
plasmid
dna
encod
influenza
viru
ha
intranas
immun
mice
liposom
system
effect
elicit
igg
iga
humor
respons
system
local
iga
level
enhanc
cellmedi
immun
respons
also
success
induc
addit
immun
mice
abl
withstand
lethal
challeng
influenza
viru
hand
intramuscular
immun
system
enhanc
igg
level
effect
iga
level
either
local
system
intranas
administr
nake
dna
fail
induc
antibodi
respons
promis
result
demonstr
potenti
intranas
liposom
dna
vaccin
system
improv
dna
vaccin
deliveri
effici
liposom
intranas
administr
khatri
et
al
modifi
surfac
liposom
coat
glycol
chitosan
major
function
glycol
chitosan
provid
mucoadhes
immun
stimul
properti
studi
cation
liposom
pcdopechol
phosphatidylcholinedioleylphosphatidylethanolaminecholesterol
use
entrap
plasmid
encod
region
hepat
b
antigen
glycol
chitosan
adsorb
liposom
surfac
electrostat
interact
hydrogen
bond
follow
intranas
administr
mice
surfac
modifi
liposom
could
elicit
humor
mucos
cellmedi
immun
respons
better
uncoat
liposom
system
potenti
exploit
intranas
dna
vaccin
respiratori
infecti
diseas
number
studi
alreadi
demonstr
potenti
liposom
dna
vaccin
system
intranas
administr
could
offer
consider
immun
protect
respiratori
infect
anim
howev
lipid
composit
differ
liposom
system
vari
greatli
current
lack
knowledg
composit
may
affect
immun
respons
enabl
util
liposom
dna
vaccin
clinic
applic
approv
better
understand
factor
govern
efficaci
immun
liposom
deliveri
system
must
first
sought
enhanc
immun
respons
dna
vaccin
adjuv
includ
formul
mani
studi
adjuv
gener
defin
agent
could
enhanc
immun
respons
vaccin
subject
antigen
dna
vaccin
sinc
deliveri
dna
major
hurdl
dna
carrier
system
use
bacteri
viral
nonvir
vector
well
cell
specif
target
ligand
discuss
also
consid
dna
vaccin
adjuv
summari
dna
vaccin
adjuv
investig
shown
tabl
section
protein
macromolecul
immunopotenti
properti
directli
involv
deliveri
dna
discuss
especi
commonli
employ
intranas
vaccin
enterotoxin
protein
exotoxin
releas
pathogen
infect
gut
enterotoxinbas
mucos
adjuv
potent
wellestablish
strategi
induct
mucos
system
immun
coadminist
protein
antigen
heatlabil
enterotoxin
lt
e
coli
cholera
enterotoxin
ct
potent
adjuv
toxic
use
human
therefor
detoxifi
mutant
enterotoxin
produc
sitedirect
mutagenesi
extens
investig
adjuv
mucos
vaccin
includ
intranas
vaccin
intranas
antigen
immun
lt
mutant
adjuv
provid
effect
protect
infecti
diseas
anim
suggest
lt
mutant
adjuv
could
induc
potent
cytotox
lymphocyt
respons
mechan
action
believ
aris
enhanc
permeat
antigen
across
epitheli
barrier
mark
increas
antigen
present
apc
mutant
ct
also
show
strong
adjuv
activ
could
retain
good
adjuv
function
administ
intranas
expect
lt
mutant
ct
mutant
similar
mechan
adjuv
activ
major
concern
intranas
administr
mutant
lt
ct
toxin
deriv
may
gain
access
central
nervou
system
olfactori
nerv
report
nativ
mutant
lt
use
adjuv
associ
develop
bell
palsi
follow
intranas
deliveri
human
risk
enterotoxin
mucos
adjuv
intranas
administr
alreadi
discuss
section
lipopolysaccharid
lp
major
compon
outer
membran
gramneg
bacteria
could
elicit
strong
immun
respons
howev
also
highli
toxic
order
make
safe
suitabl
vaccin
adjuv
lp
deriv
produc
reduc
endotox
effect
retain
immunostimulatori
function
monophosphoryl
lipid
mpl
one
exampl
lp
deriv
investig
vaccin
adjuv
mpl
prepar
remov
phosphat
fatti
acid
group
lipid
salmonella
minnesola
mpl
thought
interact
tolllik
receptor
apc
demonstr
mpl
could
activ
macrophag
increas
cytokin
secret
henc
immun
respons
regard
safeti
mpl
appear
retain
immunogen
activ
lp
significantli
reduc
toxic
mpl
extens
evalu
clinic
adjuv
variou
diseas
includ
infecti
diseas
accept
profil
advers
effect
mpl
use
success
mucos
adjuv
formul
liposom
virosom
intranas
administr
anim
cytokin
small
protein
import
regul
immunolog
respons
recruit
stimul
cell
directli
act
infect
cell
potenti
natur
adjuv
dna
vaccin
cytokin
evalu
possibl
dna
intranas
vaccin
adjuv
includ
gmcsf
particular
found
effect
mucos
adjuv
lynch
et
al
demonstr
intranas
administr
pneumococc
polysaccharid
conjug
vaccin
presenc
abl
enhanc
system
mucos
immun
respons
pneumococci
mice
howev
cytokin
short
halflif
vivo
poor
stabil
also
expens
associ
dose
relat
toxic
therefor
molecul
may
suitabl
use
adjuv
vaccin
design
protect
infecti
diseas
nevertheless
intranas
administr
induc
less
toxic
parenter
administr
altern
cytokin
express
plasmid
dna
allow
longlast
express
vivo
reduc
cost
product
emerg
new
antimicrobialresist
bacteria
virus
eas
transmiss
especi
respiratori
pathogen
respiratori
infect
becom
seriou
threat
human
health
safe
effect
vaccin
import
safeguard
public
health
intranas
dna
vaccin
appear
promis
noninvas
approach
provid
protect
variou
infecti
diseas
evid
show
intranas
dna
vaccin
could
elicit
strong
longlast
humor
well
cellmedi
immun
respons
mani
anim
model
dna
vaccin
alreadi
success
use
veterinari
product
protect
infect
immunogen
need
enhanc
make
suitabl
human
use
improv
dna
deliveri
formul
one
sever
strategi
enhanc
immun
respons
variou
studi
demonstr
signific
improv
immun
respons
could
achiev
employ
dna
carrier
system
target
dna
vaccin
apc
dna
vaccin
gener
good
safeti
profil
potenti
toxic
associ
dna
deliveri
system
especi
use
high
concentr
must
neglect
dna
vaccin
may
circumv
mani
problem
associ
convent
vaccin
high
cost
protein
vaccin
purif
bacterialvir
inactiv
attenu
process
incorrect
fold
antigen
viral
mutat
risk
therebi
offer
safer
altern
benefit
human
addit
mass
manufactur
dna
vaccin
easier
faster
dna
product
usual
highli
stabl
effect
intranas
dna
vaccin
deliveri
system
identifi
optim
deliveri
technolog
platform
could
establish
allow
develop
dna
vaccin
formul
differ
infecti
diseas
futur
